Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death

Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone

(2008) T Šimůnek et al.   BRITISH JOURNAL OF PHARMACOLOGY

Differences in doxorubicin-induced apoptotic signaling in adult and immature cardiomyocytes

(2008) Eugene A. Konorev et al.   FREE RADICAL BIOLOGY AND MEDICINE

Ultrastructural definition of apoptosis in heart failure

(2008) Eloisa Arbustini et al.   HEART FAILURE REVIEWS

Anthracycline Cardiotoxicity: From Bench to Bedside

(2008) Luca Gianni et al.   JOURNAL OF CLINICAL ONCOLOGY

Deferiprone Does Not Protect against Chronic Anthracycline Cardiotoxicity in Vivo

(2008) O. Popelova et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy

(2008) Elke Martin et al.   TOXICOLOGY